Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

ABSTRACT Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown. Areas covered: We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. We also review determinants of initial responses and of their persistence. Expert commentary: Persistence of EBOV-GP-specific antibody responses is strong at 2 years – currently the longest post-vaccination interval studied – after a single injection. Vaccine dose predicts persistence of seropositivity, though the magnitude of antibody responses at later time points becomes less dose-dependent. Vaccine-related arthritis is a significant predictor of both persistence and magnitude of the antibody response.

[1]  D. Medaglini,et al.  Correlates of vaccine-induced protective immunity against Ebola virus disease. , 2018, Seminars in immunology.

[2]  T. Monath,et al.  Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. , 2018, The Lancet. Infectious diseases.

[3]  A. Schuchat,et al.  The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV[INCREMENT]G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak , 2018, The Journal of infectious diseases.

[4]  T. Monath,et al.  Phase 2 Placebo‐Controlled Trial of Two Vaccines to Prevent Ebola in Liberia , 2017, The New England journal of medicine.

[5]  M. Kieny,et al.  Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial , 2017, PLoS medicine.

[6]  Rodolphe Thiébaut,et al.  Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV , 2017, Cell Reports.

[7]  W. J. Ramsey,et al.  Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. , 2017, The Lancet. Infectious diseases.

[8]  W. J. Ramsey,et al.  Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial , 2017, Canadian Medical Association Journal.

[9]  H. Feldmann,et al.  Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection , 2017, Scientific Reports.

[10]  T. Monath,et al.  A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa , 2017, Science Translational Medicine.

[11]  M. Addo,et al.  Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization☆ , 2017, EBioMedicine.

[12]  G. Kobinger,et al.  The ongoing evolution of antibody-based treatments for Ebola virus infection. , 2017, Immunotherapy.

[13]  G. Mattiuzzo,et al.  Comparison of platform technologies for assaying antibody to Ebola virus , 2017, Vaccine.

[14]  John-Arne Røttingen,et al.  Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.

[15]  W. J. Ramsey,et al.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine , 2017, The New England journal of medicine.

[16]  R. Davey,et al.  Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies , 2016, Nature Medicine.

[17]  Michael A Proschan,et al.  A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. , 2016, The New England journal of medicine.

[18]  Desmond E. Williams,et al.  Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data. , 2016, The Lancet. Global health.

[19]  G. Wilkie,et al.  Late Ebola virus relapse causing meningoencephalitis: a case report , 2016, The Lancet.

[20]  Jason A. Regules,et al.  Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine , 2016, Scientific Reports.

[21]  M. Altfeld,et al.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.

[22]  S. Plotkin Zika as still another argument for a new path to vaccine development , 2016, Clinical Microbiology and Infection.

[23]  F. Spertini,et al.  Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. , 2016, The Lancet. Infectious diseases.

[24]  James D. Campbell,et al.  Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial , 2016, The Lancet. Infectious diseases.

[25]  S. Yerly,et al.  The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.

[26]  Edward Wright,et al.  A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. , 2015, The New England journal of medicine.

[27]  M. Katze,et al.  Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates , 2013, Proceedings of the National Academy of Sciences.

[28]  Majidat A. Muhammad,et al.  Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease , 2012, Proceedings of the National Academy of Sciences.

[29]  K. Mansfield,et al.  Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates , 2012, PLoS neglected tropical diseases.

[30]  H. Feldmann,et al.  Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. , 2011, The Journal of infectious diseases.

[31]  X. Qiu,et al.  Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses , 2009, PloS one.

[32]  N. Sullivan,et al.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.

[33]  Heinz Feldmann,et al.  Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus , 2009, Journal of Virology.

[34]  Steven J M Jones,et al.  Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates , 2008, PLoS pathogens.

[35]  L. Fernando,et al.  Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. , 2007, The Journal of infectious diseases.

[36]  N. Sullivan,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[37]  H. Feldmann,et al.  Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.

[38]  N. Sullivan,et al.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.